Literature DB >> 2664170

Lupus pneumonitis and anti-SSA(Ro) antibodies.

D W Boulware1, M T Hedgpeth.   

Abstract

Interstitial pneumonitis has previously been thought to be an uncommon feature in systemic lupus erythematosus (SLE). A review of 63 patients with SLE from 1984 to 1987 at Tulane University revealed a frequency of 25.4% (N = 16) of lupus pneumonitis. Serologic testing for antibodies to SSA(Ro) revealed that 81% (13 of the 16) of the patients with lupus pneumonitis have anti-SSA(Ro) antibodies, compared to a frequency of 38% (24 of the 63) for the entire group with SLE (p less 0.001). The association of lupus pneumonitis and anti-SSA(Ro) antibodies is discussed in light of a speculative immunopathogenic role for the antibody to SSA(Ro) antigen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664170

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Interstitial lung disease and Sjögren's syndrome in primary biliary cirrhosis: a causal or casual association?

Authors:  Bin Liu; Feng Chun Zhang; Zhou Li Zhang; Wen Zhang; Li Xia Gao
Journal:  Clin Rheumatol       Date:  2008-05-30       Impact factor: 2.980

Review 2.  Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases.

Authors:  P Youinou; Y Adler; S Muller; A Lamour; D Baron; R L Humbel
Journal:  Clin Rev Allergy       Date:  1994

3.  Interstitial lung disease and pulmonary hypertension responsive to low-dose ultraviolet A1 irradiation in lupus.

Authors:  Benjamin Jabara; Mollie Dahlgren; Hugh McGrath
Journal:  J Clin Rheumatol       Date:  2010-06       Impact factor: 3.517

4.  Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience.

Authors:  Linda M Mileti; Mary E Strek; Timothy B Niewold; James J Curran; Nadera J Sweiss
Journal:  J Clin Rheumatol       Date:  2009-08       Impact factor: 3.517

5.  Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; A M Teppo; C Friman
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

6.  Lupus pneumonitis presenting with high titre of anti-Ro antibody.

Authors:  Mei-Chuan Chen; Yueh-Lin Wu; Kai-Ling Lee; Kevin S Lai; Chi-Li Chung
Journal:  Respirol Case Rep       Date:  2017-10-27

Review 7.  Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus.

Authors:  H McGrath
Journal:  Lupus       Date:  2017-05-08       Impact factor: 2.911

8.  Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort.

Authors:  Javier Narváez; Helena Borrell; Fernando Sánchez-Alonso; Iñigo Rúa-Figueroa; Francisco Javier López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Antonio Fernández-Nebro; Alejandro Olivé; José Luis Andreu; Víctor Martínez-Taboada; Joan Miquel Nolla; José María Pego-Reigosa
Journal:  Arthritis Res Ther       Date:  2018-12-19       Impact factor: 5.156

9.  Systemic Lupus Erythematosus Presenting as Acute Lupus Pneumonitis during Pregnancy.

Authors:  Marlene Marte Furment; Suyansh Sharma; Sangeetha Pabolu
Journal:  Case Rep Rheumatol       Date:  2020-12-21

Review 10.  Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus.

Authors:  Raj Amarnani; Su-Ann Yeoh; Emma K Denneny; Chris Wincup
Journal:  Front Med (Lausanne)       Date:  2021-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.